Navigation Links
Drug Combo Halves Death Risk for Severe COPD Patients
Date:12/28/2007

Salmeterol plus fluticasone therapy led to better health, large trial finds

FRIDAY, Dec. 28 (HealthDay News) -- People suffering with chronic obstructive pulmonary disease (COPD) may find that combining two currently available medications halves their risk of death within two years as well and improves their overall health status and quality of life, new research suggests.

The conclusion is drawn from the first human trial to compare treatment of COPD with a combination of salmeterol and fluticasone [SFC] to tiotropium therapy. The medications in the study are currently prescribed to improve breathing among patients with COPD or asthma.

COPD, a chronic disease that makes it difficult to breathe easily, is the fourth leading cause of death in the United States. More than 11 million people are diagnosed with the condition, according to the American Lung Association.

"Although we found no difference in the overall rate of exacerbations between treatment groups, SFC treatment was associated with better health status, fewer patient withdrawals, and a lower mortality rate than occurred during tiotropium therapy," study author Dr. Jadwiga Wedzicha, of the Royal Free & University College Medical School in London, said in a prepared statement.

Writing in the January issue of the American Journal of Respiratory and Critical Care Medicine, researchers described the results of a two-year trial of SFC or tiotropium for 1,323 patients with severe COPD. The researchers analyzed number and type of exacerbations, health status, lung function and study withdrawal rate. Patients were randomly assigned to one of the two treatment plans, and neither they nor their doctors knew which treatment they were receiving.

Exacerbations are periods of time when people with COPD have a harder time breathing freely, characterized by wheezing, coughing and shortness of breath. People may need medical assistance during an exacerbation. Neither treatment was more successful in reducing the number of exacerbations patients experienced, although the researchers noted that oral steroids were used more often to control exacerbations among people taking tiotropium. People on SFC were more likely to require antibiotics.

However, patients in the SFC arm of the trial were 50 percent less likely to die from any cause during the two years of the study. They were also less likely to drop out of the trial.

The researchers called for further research to understand the mechanisms behind the therapies.

More information

To learn more about COPD, visit the American Lung Association.



-- Madeline Vann



SOURCE: American Thoracic Society, news release, Dec. 28, 2007


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Radiation and drug combo helps boost efficacy of lung cancer treatment
2. Aerobic, Weight Training Combo Best Against Diabetes
3. New antibiotic drug combo to speed up treatment of tuberculosis
4. Drug Combo Helps Fight Marfan Syndrome
5. Drug Combo Blocks Pain Without Impairing Movement
6. Two-Drug Combo Fights Brain Tumors
7. CPR, Defibrillator Combo Boosts Cardiac Incident Survival
8. Drug Combo Boosts Multiple Myeloma Survival
9. Drug Combos Effective Against Rheumatoid Arthritis
10. Combo PET/CT Scan Helps Spot Breast Cancers Spread
11. Drug Combo With Antibiotic May Slow MS Progression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... R.I. (PRWEB) , ... January 19, 2017 , ... With the cold weather here, many ... , Snow blowers are efficient when clearing large amounts of snow, but they can be ... from the U.S. Consumer Product Safety Commission for the proper use of snow blowers:, ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... engineers, and scientists from around the world, announces the launch of its newly ... and easy portal to research breakthroughs and trending news, vital information on upcoming ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... has recently unveiled impressive transportable capabilities with their iMedHD2™ Portable Teleultrasound ... extension to RMT technology that delivers HD, dynamic, streaming ultrasound images and video ...
(Date:1/19/2017)... ... January 19, 2017 , ... WholeHealth is announcing ... Drs. Alexander Paziotopoulos, Andrew Petersen and Trish Henrie-Barrus will be present Saturday and ... leading recovery program. , “We know it’s easy to get carried away ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... American Board of Dermatology and fellowship trained Mohs and cosmetic surgeon. After extensive ... Health, Dr. Li completed his internship in internal medicine at the Emory University ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... , January 19, 2017 ... announced that the U.S. Food and Drug Administration (FDA) ... a New Drug Application (NDA) for SHP465, a long-acting, ... as a potential once-daily treatment for Attention-Deficit/Hyperactivity Disorder (ADHD). ... or around June 20, 2017, the designated Prescription Drug ...
(Date:1/19/2017)... -- Pfizer joins Astex, AstraZeneca, GlaxoSmithKline, ...   Major research investment to work ...   The Milner Therapeutics Institute today announces ... partner to the Milner Therapeutics Consortium. Pfizer has agreed ... of materials between industry and academia and allocation of ...
(Date:1/19/2017)... 2017 While various reports ... reducing the FDA,s regulatory strictness as a way ... drug industry, many of the leading biotech and ... and development of advanced drug treatments and therapies.  ... developments include:  Moleculin Biotech, Inc., (NASDAQ: ...
Breaking Medicine Technology: